Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1996 Nov;64(11):4659–4664. doi: 10.1128/iai.64.11.4659-4664.1996

A riboflavin auxotroph of Actinobacillus pleuropneumoniae is attenuated in swine.

T E Fuller 1, B J Thacker 1, M H Mulks 1
PMCID: PMC174428  PMID: 8890222

Abstract

Actinobacillus pleuropneumoniae is the etiological agent of a highly contagious and often fatal pleuropneumonia in swine. A riboflavin-requiring mutant of A. pleuropneumoniae serotype 1, designated AP233, was constructed by deleting a portion of the riboflavin biosynthetic operon (ribGBAH) and replacing it with a gene cassette encoding kanamycin resistance. The genes affected included both the alpha- and beta-subunits of riboflavin synthase as well as a bifunctional enzyme containing GTP cyclohydrase and 3,4-dihydroxy-2-butanone-4-phosphate synthase activities. AP233 was unable to grow in the absence of exogenous riboflavin but otherwise was phenotypically identical to the parent wild-type strain. Experimental infection studies with pigs demonstrated that the riboflavin-requiring mutant was unable to cause disease, on the basis of mortality, lung pathology, and clinical signs, at dosages as high as 500 times the normal 50% lethal dose for the wild-type parent. This is the first demonstration of the attenuation of A. pleuropneumoniae by introduction of a defined mutation in a metabolic gene and the first demonstration that mutations in the genes required for riboflavin biosynthesis can lead to attenuation in a bacterial pathogen.

Full Text

The Full Text of this article is available as a PDF (287.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahmed Z. U., Sarker M. R., Sack D. A. Protection of adult rabbits and monkeys from lethal shigellosis by oral immunization with a thymine-requiring and temperature-sensitive mutant of Shigella flexneri Y. Vaccine. 1990 Apr;8(2):153–158. doi: 10.1016/0264-410x(90)90139-d. [DOI] [PubMed] [Google Scholar]
  2. Collins L. V., Attridge S., Hackett J. Mutations at rfc or pmi attenuate Salmonella typhimurium virulence for mice. Infect Immun. 1991 Mar;59(3):1079–1085. doi: 10.1128/iai.59.3.1079-1085.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fenwick B., Henry S. Porcine pleuropneumonia. J Am Vet Med Assoc. 1994 May 1;204(9):1334–1340. [PubMed] [Google Scholar]
  4. Fuller T. E., Mulks M. H. Characterization of Actinobacillus pleuropneumoniae riboflavin biosynthesis genes. J Bacteriol. 1995 Dec;177(24):7265–7270. doi: 10.1128/jb.177.24.7265-7270.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Hoiseth S. K., Stocker B. A. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature. 1981 May 21;291(5812):238–239. doi: 10.1038/291238a0. [DOI] [PubMed] [Google Scholar]
  6. Homchampa P., Strugnell R. A., Adler B. Construction and vaccine potential of an aroA mutant of Pasteurella haemolytica. Vet Microbiol. 1994 Sep;42(1):35–44. doi: 10.1016/0378-1135(94)90075-2. [DOI] [PubMed] [Google Scholar]
  7. Homchampa P., Strugnell R. A., Adler B. Molecular analysis of the aroA gene of Pasteurella multocida and vaccine potential of a constructed aroA mutant. Mol Microbiol. 1992 Dec;6(23):3585–3593. doi: 10.1111/j.1365-2958.1992.tb01794.x. [DOI] [PubMed] [Google Scholar]
  8. Hunneman W. A. Incidence, economic effects, and control of Haemophilus pleuropneumoniae infections in pigs. Vet Q. 1986 Jan;8(1):83–87. doi: 10.1080/01652176.1986.9694024. [DOI] [PubMed] [Google Scholar]
  9. Inzana T. J., Todd J., Veit H. P. Safety, stability, and efficacy of noncapsulated mutants of Actinobacillus pleuropneumoniae for use in live vaccines. Infect Immun. 1993 May;61(5):1682–1686. doi: 10.1128/iai.61.5.1682-1686.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Jolie R. A., Mulks M. H., Thacker B. J. Antigenic differences within Actinobacillus pleuropneumoniae serotype 1. Vet Microbiol. 1994 Feb;38(4):329–349. doi: 10.1016/0378-1135(94)90151-1. [DOI] [PubMed] [Google Scholar]
  11. Jolie R. A., Mulks M. H., Thacker B. J. Cross-protection experiments in pigs vaccinated with Actinobacillus pleuropneumoniae subtypes 1A and 1B. Vet Microbiol. 1995 Aug;45(4):383–391. doi: 10.1016/0378-1135(94)00145-m. [DOI] [PubMed] [Google Scholar]
  12. Kelly S. M., Bosecker B. A., Curtiss R., 3rd Characterization and protective properties of attenuated mutants of Salmonella choleraesuis. Infect Immun. 1992 Nov;60(11):4881–4890. doi: 10.1128/iai.60.11.4881-4890.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kimura A., Hansen E. J. Antigenic and phenotypic variations of Haemophilus influenzae type b lipopolysaccharide and their relationship to virulence. Infect Immun. 1986 Jan;51(1):69–79. doi: 10.1128/iai.51.1.69-79.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kärnell A., Cam P. D., Verma N., Lindberg A. A. AroD deletion attenuates Shigella flexneri strain 2457T and makes it a safe and efficacious oral vaccine in monkeys. Vaccine. 1993;11(8):830–836. doi: 10.1016/0264-410x(93)90358-5. [DOI] [PubMed] [Google Scholar]
  15. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  16. Lindberg A. A., Kärnell A., Stocker B. A., Katakura S., Sweiha H., Reinholt F. P. Development of an auxotrophic oral live Shigella flexneri vaccine. Vaccine. 1988 Apr;6(2):146–150. doi: 10.1016/s0264-410x(88)80018-5. [DOI] [PubMed] [Google Scholar]
  17. Miller V. L., Mekalanos J. J. A novel suicide vector and its use in construction of insertion mutations: osmoregulation of outer membrane proteins and virulence determinants in Vibrio cholerae requires toxR. J Bacteriol. 1988 Jun;170(6):2575–2583. doi: 10.1128/jb.170.6.2575-2583.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Mulks M. H., Buysse J. M. A targeted mutagenesis system for Actinobacillus pleuropneumoniae. Gene. 1995 Nov 7;165(1):61–66. doi: 10.1016/0378-1119(95)00528-e. [DOI] [PubMed] [Google Scholar]
  19. Nielsen R. Haemophilus parahaemolyticus serotypes. Pathogenicity and cross immunity. Nord Vet Med. 1979 Oct;31(10):407–413. [PubMed] [Google Scholar]
  20. Nielsen R. Haemophilus pleuropneumoniae serotypes--cross protection experiments. Nord Vet Med. 1984 Jul-Aug;36(7-8):221–234. [PubMed] [Google Scholar]
  21. Nielsen R. Pleuropneumonia of swine caused by Haemophilus parahaemolyticus. Studies on the protection obtained by vaccination. Nord Vet Med. 1976 Jul-Aug;28(7-8):337–348. [PubMed] [Google Scholar]
  22. Nielsen R. Serological and immunological studies of pleuropneumonia of swine caused by Haemophilus parahaemolyticus. Acta Vet Scand. 1974;15(1):80–89. doi: 10.1186/BF03547495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Nnalue N. A., Stocker B. A. Test of the virulence and live-vaccine efficacy of auxotrophic and galE derivatives of Salmonella choleraesuis. Infect Immun. 1987 Apr;55(4):955–962. doi: 10.1128/iai.55.4.955-962.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. O'Callaghan D., Maskell D., Liew F. Y., Easmon C. S., Dougan G. Characterization of aromatic- and purine-dependent Salmonella typhimurium: attention, persistence, and ability to induce protective immunity in BALB/c mice. Infect Immun. 1988 Feb;56(2):419–423. doi: 10.1128/iai.56.2.419-423.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Rosendal S., Carpenter D. S., Mitchell W. R., Wilson M. R. Vaccination against pleuropneumonia of pigs caused by Haemophilus pleuropneumoniae. Can Vet J. 1981 Feb;22(2):34–35. [PMC free article] [PubMed] [Google Scholar]
  26. Schott K., Kellermann J., Lottspeich F., Bacher A. Riboflavin synthases of Bacillus subtilis. Purification and amino acid sequence of the alpha subunit. J Biol Chem. 1990 Mar 15;265(8):4204–4209. [PubMed] [Google Scholar]
  27. Sebunya T. N., Saunders J. R. Haemophilus pleuropneumoniae infection in swine: a review. J Am Vet Med Assoc. 1983 Jun 15;182(12):1331–1337. [PubMed] [Google Scholar]
  28. Sigwart D. F., Stocker B. A., Clements J. D. Effect of a purA mutation on efficacy of Salmonella live-vaccine vectors. Infect Immun. 1989 Jun;57(6):1858–1861. doi: 10.1128/iai.57.6.1858-1861.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Tacket C. O., Hone D. M., Curtiss R., 3rd, Kelly S. M., Losonsky G., Guers L., Harris A. M., Edelman R., Levine M. M. Comparison of the safety and immunogenicity of delta aroC delta aroD and delta cya delta crp Salmonella typhi strains in adult volunteers. Infect Immun. 1992 Feb;60(2):536–541. doi: 10.1128/iai.60.2.536-541.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Vaughan L. M., Smith P. R., Foster T. J. An aromatic-dependent mutant of the fish pathogen Aeromonas salmonicida is attenuated in fish and is effective as a live vaccine against the salmonid disease furunculosis. Infect Immun. 1993 May;61(5):2172–2181. doi: 10.1128/iai.61.5.2172-2181.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Vieira J., Messing J. The pUC plasmids, an M13mp7-derived system for insertion mutagenesis and sequencing with synthetic universal primers. Gene. 1982 Oct;19(3):259–268. doi: 10.1016/0378-1119(82)90015-4. [DOI] [PubMed] [Google Scholar]
  32. West S. E., Romero M. J., Regassa L. B., Zielinski N. A., Welch R. A. Construction of Actinobacillus pleuropneumoniae-Escherichia coli shuttle vectors: expression of antibiotic-resistance genes. Gene. 1995 Jul 4;160(1):81–86. doi: 10.1016/0378-1119(95)00236-y. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES